Bristol-Myers Squibb (BMY) stock in plain English
Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.
Change shown by the quote provider. Data may be delayed.
What does Bristol-Myers Squibb (BMY) do?
Bristol-Myers Squibb Co (BMY) is a U.S.-listed company in Healthcare (Drug Manufacturers - General). What it does: Manufactures and sells specialty prescription medicines for cardiovascular diseases, cancer, and immune disorders globally. Discovers, manufactures, and distributes prescription biopharmaceutical medicines across oncology, immunology. It is worth $119.25B on the market and sold $50.11B over the last year.
- Market cap
- $119.25B
- P/E ratio
- 12.9×
- Annual sales
- $50.11B
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Brief updated
- Nov 07, 2026
Brands and businesses behind BMY
- Eliquis: Prescription blood thinner that generates revenue through sales to treat and prevent blood clots and strokes.
- Opdivo: Prescription immunotherapy medicine that generates revenue by treating various forms of advanced cancer.
- Revlimid: Prescription oral cancer medicine that earns revenue from treating multiple myeloma and myelodysplastic syndromes.
- Pomalyst: Prescription oral therapy that earns revenue by treating patients with relapsed or refractory multiple myeloma.
- Yervoy: Prescription immune oncology drug that earns revenue by treating advanced melanoma and other malignant cancers.
- Orencia: Prescription biologic therapy that generates revenue through treatments for rheumatoid and psoriatic arthritis.
BMY’s flags, in plain English
Each flag is a number from Bristol-Myers Squibb’s reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 07, 2026.
Earns Its Keep
Earns 44.1% a year on shareholders' money. The company earns a healthy return on the money its shareholders have put in.
Wide Gross Margin
Gross margin of 66.3% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.
Cheap on Cash Flow
Priced at 12.8 times the cash it generates each year. The share price is low compared with the cash the business actually brings in, and cash is harder to dress up than profit.
Debt Is Driving
Heavy debt, 191% of shareholder equity. The company owes a lot compared with what it earns. Lenders get paid before shareholders, which leaves management fewer options in a weak year.
2 more green flags and 1 more risk note open with the free trial. Try it free for 7 days.
Questions about BMY
How big is Bristol-Myers Squibb?
Bristol-Myers Squibb’s market cap is $119.25B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $50.11B: what customers paid the company over the last year, before any costs.
What is BMY’s P/E ratio?
BMY’s P/E ratio is 12.9×. Investors pay about 12.9 dollars for each dollar of the company’s yearly profit. A low number can mean a bargain or a problem, so read it next to the flags.
What could go wrong with BMY?
Key blockbuster medicines face generic market entry and government price negotiation, eroding revenue from Eliquis and Revlimid. That is one risk on Bristol-Myers Squibb’s card. Its first risk flag is Debt Is Driving, explained above. The card holds 1 more risk note for trial accounts. A flag reads what the company reported. It does not predict the price.
Where do these numbers come from?
From Bristol-Myers Squibb’s own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. BMY’s filings on SEC.gov. The Margin Monkey is research, not advice.
